Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102)
The PREDICT trial represents a paradigm shift toward molecular characterization and real‑time decision making in metastatic castration‑resistant prostate cancer (mCRPC).
This phase II, biomarker‑driven, multi‑arm umbrella study evaluates precision treatment strategies for metastatic castration‑resistant prostate cancer (mCRPC) using DNA and RNA profiling to allocate patients to therapeutic arms informed by a molecular tumor board. The study aims to establish a scalable precision oncology framework.
Metastatic castration‑resistant prostate cancer remains a lethal disease with limited durable responses to approved therapies, highlighting a critical need for more personalized and durable treatment strategies.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience